<DOC>
	<DOCNO>NCT01481831</DOCNO>
	<brief_summary>This purpose study evaluate efficacy safety single repeat dos palonosetron hydrochloride prevent nausea vomit cause moderate highly emetogenic chemotherapy patient .</brief_summary>
	<brief_title>Efficacy Safety Palonosetron Hydrochloride Prevention Nausea Vomiting</brief_title>
	<detailed_description>Group I ( Highly Emetogenic Chemotherapy ) : Patients accept chemotherapy include Cisplatin≥50mg/m2 , Carmustine &gt; 250mg/m2 , Cyclophosphamide &gt; 1500mg/m2 , Dacarbazine &gt; 60mg/m2 , Doxorubicin &gt; 60mg/m2 , Epirubicin &gt; 90mg/m2 , IFO≥10g/m2 AC program . Group II ( Moderately Emetogenic Chemotherapy ) : Patients accept chemotherapy include dose Carboplatin , Daunorubicin , Oaliplatin , Irinotecan , Doxorubicin &lt; 60mg/m2 ( include liposomal doxorubicin ) , Epirubicin≤90mg/m2 , Carmustine≤250mg/m2 , Methotrexate≥250mg/m2 , Cyclophosphamide≤1500mg/m2 , Arabinoside &gt; 200mg/m2 , IFO &lt; 10g/m2 , Cisplatin≥50mg/m2 . Total subject : 1000 , single dose palonosetron group 500 patient , repeat dos palonosetron group 500 patient . According study subject receive highly emetogenic chemotherapy moderately emetogenic chemotherapy , subject stratify randomize .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>1 . Patients candidate chemotherapy treatment , histologically cytologically confirm malignant disease ; 2 . The concrete chemotherapy plan limit , group I ( Highly Emetogenic Chemotherapy ) , group II ( Moderately Emetogenic Chemotherapy ) ; 3 . Male female age 1875 year , ECOG≤2 , estimate survival time≥3 month ; 4 . WBC≥3.0×109/L , ANC≥1.5×109/L , PLT≥80×109/L , total bilirubin≤1.5×ULN ( Normal value upper limit ) , AST ALT≤2.5×ULN ( With transferability liver cancer≤5×ULN ) , Cr BUN≤1.5×ULN , electrolyte electrocardiogram normal , conforms chemotherapy adaptation ; 5 . Patients apart previous chemotherapy finish 2 week ( include 2 week ) ; 6 . Patients voluntarily sign consent form . 1 . Pregnancy , patient breast feeding ; 2 . Patients accept radiotherapy experimental period ; 3 . Gastric outlet intestinal obstruction ; 4 . Patients serious heart disease , liver kidney disease , metabolism function disorder ; 5 . Patients epilepsy , use psychotropic drug calm drug ; 6 . Received drug potential antiemetic efficacy , experience vomiting , nausea retch 24 hour prior chemotherapy ; 7 . Patients transferability brain tumor , vomit cause skull high pressure , speak sickness situation adverse reaction self ; 8 . Patients know hypersensitivity 5HT3 antagonist ; 9 . Patients chemotherapy contraindication ; 10 . Patients participate , participate Clinical study new drug within 2 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>